# Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease

> **NCT07298343** · PHASE2 · RECRUITING · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 356 (estimated)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** ZED1227 + SIGE
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07298343
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-10
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 356 (ESTIMATED)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07298343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07298343, "Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07298343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*